Figure 2 | Scientific Reports

Figure 2

From: The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease

Figure 2

Saroglitazar decreased liver injury and dyslipidemia. DIAMOND mice fed CDNW or WDSW for 12 weeks were administered pioglitazone, saroglitazar or vehicle control for another 12 weeks. At the end of 24 weeks following dietary intervention and treatment, mice were fasted overnight and blood was collected. (A) serum cholesterol, (B) serum non HDL, (C) serum AST, (D) serum ALT. Data are expressed as the mean ± SEM for 6–12 mice per group. #p < 0.05, ##p < 0.001 compared to CDNW; *p < 0.05, **p < 0.001 compared to WDSW, vehicle control. HDL, high density lipoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase.

Back to article page